Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hoth Therapeutics, Inc. (HOTH)
USD0.89
+0.09 (+10.65%)
US NASDAQ Healthcare Biotechnology
Address
1177 Avenue of the Americas 10036
New York, NY, US
New York, NY, US
CEO
Robb Knie
Website
hoththerapeutics.com
IPO
2019-02-15
ISIN US44148G2049
Also trades on
NASDAQ Capital Market · HOTH (USD)
NASDAQ Global Market · RKTO (USD)
Description
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.89
+0.09 (+10.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
0.53
Float Shares
12.71M
Free Float %
95.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.19% | -37.07% | +92.51% | +30.26% | +8.40% | +30.30% | +8.40% | -57.00% | -96.78% | -99.40% | -99.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
0.89
DCF (Unlevered)
0.40
-55.3%
DCF (Levered)
0.45
-49.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-16.61
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+29.7% ★ Q1'26: +52.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -9,279.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+116.6% Q1'26: +61.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 177.52M (-100.0%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
131.05M
131.05M – 131.05M
|
196.65M
196.65M – 196.65M
+50.1% YoY
|
| EBITDA |
27.1K
|
-11.11M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-8.19M
|
-11.11M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-8.19M
est: -8.67M (+5.6%)
|
-12.47M
est: -11.61M (-7.4%)
|
-8.20M
-8.20M – -8.20M
+29.3% YoY
|
-9.72M
-9.72M – -9.72M
-18.4% YoY
|
-16.42M
-16.42M – -16.42M
-69.0% YoY
|
15.88M
15.88M – 15.88M
+196.7% YoY
|
28.72M
28.72M – 28.72M
+80.9% YoY
|
| SGA |
4.97M
|
6.41M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.28
est: -1.36 (+5.9%)
|
-0.90
est: -0.84 (-7.0%)
|
-0.59
-0.59 – -0.59
+29.3% YoY
|
-0.70
-0.70 – -0.70
-18.4% YoY
|
-1.19
-1.19 – -1.19
-69.0% YoY
|
1.15
1.15 – 1.15
+196.7% YoY
|
2.08
2.08 – 2.08
+80.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
7
Total invested
345.8K
Insider transactions (90d)
0
Beneficial owners (>5%)
16
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Spherix Incorporated | 1.64M | 16.20% | 1.64M | — | 1.64M | — | CO | United States | 2020-02-28 | ↗ |
| 2 | Daniel B. Asher | 1.43M | 5.60% | — | 1.43M | — | 1.43M | HC, IN | United States of America | 2022-02-11 | ↗ |
| 3 | Intracoastal Capital LLC | 1.43M | 5.60% | — | 1.43M | — | 1.43M | OO | Delaware | 2022-02-11 | ↗ |
| 4 | Mitchell P. Kopin | 1.43M | 5.60% | — | 1.43M | — | 1.43M | HC, IN | United States of America | 2022-02-11 | ↗ |
| 5 | Richard Abbe | 1.27M | 5.50% | 354.4K | 911.4K | 354.4K | 1.27M | HC, IN | United States of America | 2021-03-18 | ↗ |
| 6 | Pharma, Inc. | 1.13M | 9.74% | 1.13M | — | 1.13M | — | CO | Delaware | 2021-02-17 | ↗ |
| 7 | Kimberly Page | 911.4K | 4.00% | — | 911.4K | — | 911.4K | IN | United States of America | 2021-03-18 | ↗ |
| 8 | Iroquois Capital Management L.L.C. | 911.4K | 3.66% | — | 911.4K | — | 911.4K | OO | Delaware | 2022-02-23 | ↗ |
| 9 | Laidlaw Holdings PLC | 799.5K | 31.00% | 799.5K | — | 799.5K | — | CO | England & Wales | 2020-07-21 | ↗ |
| 10 | Jeff Easton | 792.3K | 3.20% | 792.3K | — | 792.3K | — | IN | United States | 2022-02-09 | ↗ |
| 11 | Lind Global Macro Fund, LP | 792.3K | 3.20% | 792.3K | — | 792.3K | — | PN | Delaware | 2022-02-09 | ↗ |
| 12 | Lind Global Partners LLC | 792.3K | 3.20% | 792.3K | — | 792.3K | — | OO | Delaware | 2022-02-09 | ↗ |
| 13 | S | 412.5K | 1.72% | — | 412.5K | — | 412.5K | OO | California, United States | 2022-02-03 | ↗ |
| 14 | Armistice Capital, LLC | 144.5K | 9.99% | — | 144.5K | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 15 | Steven Boyd | 144.5K | 9.99% | — | 144.5K | — | — | HC, IN | United States of America | 2023-02-14 | ↗ |
| 16 | Matthew Eitner | 18.8K | 0.14% | 18.8K | — | 18.8K | — | IN | States | 2021-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
7
-14 vs prev Q
New positions
3
Closed positions
17
Increased
5
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | DRW SECURITIES, LLC | 259.7K +259.7K (+100.0%) | 257.1K +257.1K (+100.0%) | 1.88% +1.884 pp | 0.01% +0.007 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 214.0K +— (+0.0%) | 211.9K -134.8K (-38.9%) | 1.55% -0.072 pp | 0.00% +0.000 pp | USD1.64 -39.6% | 12 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 181.1K +27.6K (+18.0%) | 179.3K -69.4K (-27.9%) | 1.31% +0.149 pp | 0.00% +0.000 pp | USD1.32 -25.0% | 11 qtrs — |
| 4 | STATE STREET CORP | 63.9K +— (+0.0%) | 63.3K -40.3K (-38.9%) | 0.46% -0.021 pp | 0.00% +0.000 pp | USD1.62 -38.9% | 2 qtrs — |
| 5 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 62.7K +62.7K (+100.0%) | 62.1K +62.1K (+100.0%) | 0.46% +0.455 pp | 0.00% +0.000 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 6 | UBS GROUP AG | 58.3K -36.3K (-38.4%) | 57.8K -95.6K (-62.3%) | 0.42% -0.295 pp | 0.00% +0.000 pp | USD1.34 -26.1% | 13 qtrs — |
| 7 | NORTHERN TRUST CORP | 42.1K +550.0 (+1.3%) | 41.6K -25.6K (-38.1%) | 0.31% -0.010 pp | 0.00% +0.000 pp | USD1.61 -38.5% | 2 qtrs — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 33.8K -210.1K (-86.1%) | 33.5K -361.6K (-91.5%) | 0.25% -1.605 pp | 0.00% -0.001 pp | USD1.62 -38.9% | 2 qtrs — |
| 9 | LIDO ADVISORS, LLC | 19.5K +— (+0.0%) | 31.6K +— (+0.0%) | 0.14% -0.007 pp | 0.00% +0.000 pp | USD1.62 -38.9% | 2 qtrs — |
| 10 | JANE STREET GROUP, LLC | 17.1K -37.8K (-68.8%) | 17.0K -72.0K (-80.9%) | 0.12% -0.293 pp | 0.00% +0.000 pp | USD1.62 -38.9% | 2 qtrs — |
| 11 | TWO SIGMA SECURITIES, LLC | 17.0K -2.1K (-10.9%) | 16.9K -14.1K (-45.5%) | 0.12% -0.022 pp | 0.00% -0.002 pp | USD1.62 -38.9% | 6 qtrs — |
| 12 | MORGAN STANLEY | 10.0K -447.0 (-4.3%) | 9.9K -7.0K (-41.5%) | 0.07% -0.007 pp | 0.00% +0.000 pp | USD1.41 -29.8% | 13 qtrs — |
| 13 | ADVISOR GROUP HOLDINGS, INC. | 2.7K -105.0 (-3.7%) | 2.7K -638.0 (-19.3%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD1.00 -1.0% | 12 qtrs — |
| 14 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.1K +1.8K (+603.7%) | 2.1K +1.6K (+330.0%) | 0.02% +0.013 pp | 0.00% +0.000 pp | USD1.02 -2.9% | 9 qtrs — |
| 15 | FLAGSHIP HARBOR ADVISORS, LLC | 2.0K +2.0K (+100.0%) | 2.0K +2.0K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.000 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 16 | JONES FINANCIAL COMPANIES LLLP | 500.00 +— (+0.0%) | 495.00 -368.0 (-42.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.00 -1.0% | 4 qtrs — |
| 17 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 350.00 +— (+0.0%) | 343.00 -217.0 (-38.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.00 -1.0% | 4 qtrs — |
| 18 | BANK OF AMERICA CORP /DE/ | 144.00 +26.0 (+22.0%) | 143.00 -48.0 (-25.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.01 -2.0% | 7 qtrs — |
| 19 | IFP ADVISORS, INC | 45.00 +45.0 (+100.0%) | 45.00 +45.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.98 +1.0% | 1 qtrs NEW |
| 20 | SBI SECURITIES CO., LTD. | 11.00 -2.0 (-15.4%) | 11.00 -10.0 (-47.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.73 +35.6% | 5 qtrs — |
| 21 | FMR LLC | 8.00 +8.0 (+100.0%) | 8.00 +8.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.88 +12.5% | 1 qtrs NEW |
| 22 | VIRTU FINANCIAL LLC | — -113.4K (-100.0%) | — -184.0K (-100.0%) | 0.00% -0.861 pp | 0.00% -0.010 pp | USD— | 6 qtrs SOLD |
| 23 | NEWEDGE ADVISORS, LLC | — -850.0 (-100.0%) | — -1.4K (-100.0%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 24 | HRT FINANCIAL LP | — -85.3K (-100.0%) | — -138.0K (-100.0%) | 0.00% -0.647 pp | 0.00% -0.001 pp | USD— | 6 qtrs SOLD |
| 25 | QUADRATURE CAPITAL LTD | — -12.8K (-100.0%) | — -20.7K (-100.0%) | 0.00% -0.097 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 26 | TWO SIGMA INVESTMENTS, LP | — -17.3K (-100.0%) | — -28.1K (-100.0%) | 0.00% -0.132 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 27 | CITIGROUP INC | — -10.6K (-100.0%) | — -17.2K (-100.0%) | 0.00% -0.081 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 28 | CITADEL ADVISORS LLC | — -143.5K (-100.0%) | — -232.4K (-100.0%) | 0.00% -1.089 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 29 | KESTRA PRIVATE WEALTH SERVICES, LLC | — -31.6K (-100.0%) | — -51.2K (-100.0%) | 0.00% -0.240 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
2.57
Bullish
Buys
1
Sells
1
Shares acquired
800.0K
Shares disposed
310.7K
Cash buys
—
Cash sales
—
Net activity
+489,256
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-28 | Knie Robb | Director / Officer | F-InKind | D | Common Stock | 310,744 | 1.21 | 376.0K | 547,387 | D | ↗ |
| 2025-08-27 | Knie Robb | Director / Officer | A-Award | A | Common Stock | 800,000 | 0.00 | — | 858,131 | D | ↗ |
| 2025-05-08 | Camarra Christopher Michael | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-01-14 | Springer Graig | Director | A-Award | A | Options | 70,000 | 1.55 | 108.5K | 70,000 | I | ↗ |
| 2025-01-14 | Knie Robb | Director / Officer | A-Award | A | Options | 93,000 | 1.55 | 144.2K | 93,000 | D | ↗ |
| 2024-08-19 | Springer Graig | Director | A-Award | A | Options | 25,000 | 0.75 | 18.9K | 25,000 | — | ↗ |
| 2024-08-19 | Sarnoff David | Director | A-Award | A | Options | 25,000 | 0.75 | 18.9K | 25,000 | — | ↗ |
| 2024-08-19 | Pavell Jeff | Director | A-Award | A | Options | 25,000 | 0.75 | 18.9K | 25,000 | — | ↗ |
| 2024-08-19 | Linsley Wayne | Director | A-Award | A | Options | 25,000 | 0.75 | 18.9K | 25,000 | — | ↗ |
| 2024-08-19 | Knie Robb | Director / Officer | A-Award | A | Options | 325,000 | 0.75 | 245.3K | 325,000 | — | ↗ |
| 2024-08-16 | Knie Robb | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 0.67 | 16.8K | 58,131 | — | ↗ |
| 2024-01-05 | Springer Graig | Director | A-Award | A | Options | 100,000 | 1.36 | 136.0K | 100,000 | — | ↗ |
| 2024-01-05 | Sarnoff David | Director | A-Award | A | Options | 25,000 | 1.36 | 34.0K | 25,000 | — | ↗ |
| 2024-01-05 | Pavell Jeff | Director | A-Award | A | Options | 25,000 | 1.36 | 34.0K | 25,000 | — | ↗ |
| 2024-01-05 | Linsley Wayne | Director | A-Award | A | Options | 25,000 | 1.36 | 34.0K | 25,000 | — | ↗ |
| 2024-01-05 | Knie Robb | Director / Officer | A-Award | A | Options | 225,000 | 1.36 | 306.0K | 225,000 | — | ↗ |
| 2023-07-17 | Springer Graig | Director | A-Award | A | Options | 20,000 | 2.59 | 51.8K | 20,000 | — | ↗ |
| 2023-07-17 | Sarnoff David | Director | A-Award | A | Options | 7,500 | 2.59 | 19.4K | 7,500 | — | ↗ |
| 2023-07-17 | Pavell Jeff | Director | A-Award | A | Options | 7,500 | 2.59 | 19.4K | 7,500 | — | ↗ |
| 2023-07-17 | Linsley Wayne | Director | A-Award | A | Options | 7,500 | 2.59 | 19.4K | 7,500 | — | ↗ |
| 2023-07-17 | Knie Robb | Director / Officer | A-Award | A | Options | 40,000 | 2.59 | 103.6K | 40,000 | — | ↗ |
| 2022-12-13 | Pavell Jeff | Director | A-Award | A | Common Stock | 5,075 | 0.00 | — | 5,075 | — | ↗ |
| 2022-12-07 | Pavell Jeff | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-19 | Knie Robb | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.39 | 3.9K | 828,259 | — | ↗ |
| 2022-09-16 | Knie Robb | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.40 | 4.0K | 818,259 | — | ↗ |
| 2022-03-16 | Springer Graig | Director | A-Award | A | Options | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-03-16 | Sarnoff David | Director | A-Award | A | Options | 40,000 | 0.59 | 23.6K | 40,000 | — | ↗ |
| 2022-03-16 | Linsley Wayne | Director | A-Award | A | Options | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-03-16 | Knie Robb | Officer | A-Award | A | Options | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2022-03-16 | Johns Stefanie | Officer | A-Award | A | Options | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2021-01-29 | Springer Graig | Director | A-Award | A | Options | 150,000 | 2.11 | 316.5K | 150,000 | — | ↗ |
| 2021-01-29 | Sarnoff David | Director | A-Award | A | Options | 33,000 | 2.11 | 69.6K | 33,000 | — | ↗ |
| 2021-01-29 | MATS VADIM | Director | A-Award | A | Options | 33,000 | 2.11 | 69.6K | 33,000 | — | ↗ |
| 2021-01-29 | Linsley Wayne | Director | A-Award | A | Options | 33,000 | 2.11 | 69.6K | 33,000 | — | ↗ |
| 2021-01-29 | Knie Robb | Director / Officer | A-Award | A | Options | 225,000 | 2.11 | 474.8K | 225,000 | — | ↗ |
| 2021-01-29 | Johns Stefanie | Officer | A-Award | A | Options | 125,000 | 2.11 | 263.8K | 125,000 | — | ↗ |
| 2020-12-31 | Knie Robb | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-31 | AIkido Pharma Inc. | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-09-08 | Johns Stefanie | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-07-21 | Springer Graig | Director | A-Award | A | Options | 45,000 | 3.05 | 137.3K | 45,000 | — | ↗ |
| 2020-07-21 | Sarnoff David | Director | A-Award | A | Options | 15,000 | 3.05 | 45.8K | 15,000 | — | ↗ |
| 2020-07-21 | RICE KENNETH L JR | Director | A-Award | A | Options | 15,000 | 3.05 | 45.8K | 15,000 | — | ↗ |
| 2020-07-21 | MATS VADIM | Director | A-Award | A | Options | 15,000 | 3.05 | 45.8K | 15,000 | — | ↗ |
| 2020-07-21 | Linsley Wayne | Director | A-Award | A | Options | 15,000 | 3.05 | 45.8K | 15,000 | — | ↗ |
| 2020-07-21 | Knie Robb | Director / Officer | A-Award | A | Options | 80,000 | 3.05 | 244.0K | 80,000 | — | ↗ |
| 2020-05-26 | Hayes Anthony | — | S-Sale | D | Common Stock, par value $0.0001 | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-04-15 | Springer Graig | Director | A-Award | A | Common Stock | 3,333 | 0.00 | — | 3,333 | — | ↗ |
| 2020-04-15 | Linsley Wayne | Director | A-Award | A | Common Stock | 3,333 | 0.00 | — | 3,333 | — | ↗ |
| 2020-02-28 | Springer Graig | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-31 | SPHERIX INC | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-31 | Knie Robb | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-31 | Hayes Anthony | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-24 | Sarnoff David | Director | J-Other | A | Options | 35,000 | 5.26 | 184.1K | 35,000 | — | ↗ |
| 2019-12-24 | RICE KENNETH L JR | Director | J-Other | A | Options | 35,000 | 5.26 | 184.1K | 35,000 | — | ↗ |
| 2019-12-24 | MATS VADIM | Director | J-Other | A | Options | 35,000 | 5.26 | 184.1K | 35,000 | — | ↗ |
| 2019-12-24 | Knie Robb | Director / Officer | J-Other | A | Options | 250,000 | 5.26 | 1.32M | 250,000 | — | ↗ |
| 2019-12-24 | Hayes Anthony | Director | J-Other | A | Options | 35,000 | 5.26 | 184.1K | 35,000 | — | ↗ |
| 2019-03-06 | Briones David S. | Officer | J-Other | A | Options | 50,000 | 5.88 | 294.0K | 50,000 | — | ↗ |
| 2019-03-05 | Briones David S. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-20 | Poor Kevin Jess | 10% Owner | C-Conversion | A | Common Stock | 750,000 | 0.00 | — | 750,000 | — | ↗ |
| 2019-02-20 | EITNER MATTHEW D. | 10% Owner | C-Conversion | A | Common Stock | 15,000 | 0.00 | — | 765,000 | — | ↗ |
| 2019-02-14 | Sarnoff David | Director | — | D | Common Stock | 0 | 0.00 | — | 25,000 | — | ↗ |
| 2019-02-14 | RICE KENNETH L JR | Director | — | D | Common Stock | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2019-02-14 | Poor Kevin Jess | 10% Owner | — | D | Series A Convertible Preferred Stock | 750,000 | 0.00 | — | 0 | — | ↗ |
| 2019-02-14 | MATS VADIM | Director | — | D | Common Stock | 0 | 0.00 | — | 37,500 | — | ↗ |
| 2019-02-14 | Knie Robb | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 808,170 | — | ↗ |
| 2019-02-14 | Hayes Anthony | Director | — | I | Common Stock | 0 | 0.00 | — | 1,700,000 | — | ↗ |
| 2019-02-14 | EITNER MATTHEW D. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 750,000 | — | ↗ |
| 2019-02-14 | AHERN JAMES P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 750,000 | — | ↗ |
| 2017-10-25 | Poor Kevin Jess | 10% Owner | — | D | Warrants | 187,500 | 1.00 | 187.5K | 0 | — | ↗ |
| 2017-10-25 | EITNER MATTHEW D. | 10% Owner | — | D | Warrants | 3,750 | 1.00 | 3.8K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
13.26M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Robb Knie Chief Executive Officer and President | 450.0K | 200.0K | — | 449.7K | — | 127.1K | 1.23M | 36.66% | ↗ |
| 2 | 2023 | Robb Knie Chief Executive Officer and President Stefanie Johns Former Chief Scientific Officer | 450.0K | 200.0K | — | 103.6K | — | 115.2K | 868.8K | 11.92% | ↗ |
| 3 | 2023 | Robb Knie Chief Executive Officer and President | 450.0K | 200.0K | — | 81.1K | — | 115.2K | 846.3K | 9.58% | ↗ |
| 4 | 2022 | Robb Knie Chief Executive Officer and President Stefanie Johns Former Chief Scientific Officer | 450.0K | 300.0K | — | 216.4K | — | 94.0K | 1.06M | 20.40% | ↗ |
| 5 | 2022 | Robb Knie Chief Executive Officer and President | 450.0K | 300.0K | — | 216.4K | — | 94.0K | 1.06M | 20.40% | ↗ |
| 6 | 2022 | Stefanie Johns Former Chief Scientific Officer | 382.4K | 20.0K | — | 108.2K | — | 185.3K | 695.9K | 15.55% | ↗ |
| 7 | 2021 | Robb Knie Chief Executive Officer and President | 400.0K | 200.0K | — | 388.9K | — | 86.3K | 1.08M | 36.17% | ↗ |
| 8 | 2021 | Jane H. Springer Vice President of Operations | 191.9K | 85.0K | — | 259.3K | — | 47.4K | 583.6K | 44.43% | ↗ |
| 9 | 2021 | Stefanie Johns Chief Scientific Officer | 253.3K | 10.0K | — | 216.1K | — | 46.9K | 526.3K | 41.05% | ↗ |
| 10 | 2021 | Stefanie Johns Former Chief Scientific Officer | 253.3K | 10.0K | — | 216.1K | — | 46.9K | 526.3K | 41.05% | ↗ |
| 11 | 2020 | Robb Knie Chief Executive Officer and President | 350.0K | 175.0K | — | 195.2K | — | 61.0K | 781.2K | 24.99% | ↗ |
| 12 | 2020 | Jane H. Springer Vice President of Operations | 175.0K | 40.0K | — | 109.8K | — | 31.0K | 355.8K | 30.86% | ↗ |
| 13 | 2020 | Stefanie Johns Chief Scientific Officer | 62.9K | — | — | — | — | 14.0K | 76.8K | 0.00% | ↗ |
| 14 | 2019 | Robb Knie Chief Executive Officer and President | 350.0K | 175.0K | — | 1.05M | — | — | 1.58M | 66.68% | ↗ |
| 15 | 2019 | Jane H. Springer Vice President of Operations | 123.8K | — | — | 210.2K | — | — | 334.0K | 62.93% | ↗ |
| 16 | 2019 | Jane H. Behrmann Vice President of Operations | 123.8K | — | — | 210.2K | — | — | 334.0K | 62.93% | ↗ |
| 17 | 2018 | Robb Knie Chief Executive Officer and President | 250.0K | — | 58.2K | — | — | — | 308.2K | 18.88% | ↗ |
| 18 | 2018 | Jane H. Behrmann Vice President of Operations | 52.1K | — | 5.0K | — | — | — | 57.1K | 8.76% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robb Knie | Founder, President, Chief Executive Officer & Chairman | 832.7K | male |
| David S. Briones | Chief Financial Officer | — | male |
| Hayley Springer | Executive Vice President of Operations | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HOTH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
